No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
www.cutiatx.comNo one on the platform currently holds 2487.HK.
No tracked institution reports a position in 2487.HK as of their last filing.
No one on the platform has traded 2487.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 20.2% | |||||
| Profit Margin % | -101.2% | -4450.9% | ||||
| Free Cash Flow Margin % | -90.1% | -2591.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $609M | +28.7% | $-0.06 | $-0.13–$0.00 | — | 2 |
| 2027 | $946M | +55.3% | $0.16 | $0.15–$0.17 | — | 2 |
| 2028 | $1.3B | +42.6% | $0.40 | $0.31–$0.49 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2487.HKCutia Therapeutics | $1.40 | +2.56% | $509M | — |
| 1521.HKFrontage Holdings Corporation | $1.10 | +0.00% | $2.2B | — |
| 2126.HKJW (Cayman) Therapeutics Co. Ltd | $2.09 | +4.76% | $870M | — |
| 2179.HKJiangsu Recbio Technology Co., Ltd. | $5.00 | +0.00% | $2.7B | — |
| 2181.HKMabpharm Limited | $0.42 | -3.45% | $1.7B | — |
| 2185.HKShanghai Bio-heart Biological Technology Co., Ltd. | $1.66 | +3.43% | $391M | — |
| 2197.HKClover Biopharmaceuticals, Ltd. | $1.97 | +1.03% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry